Because adjuvant chemotherapy with temozolomide is limited by the action of O-6-methylguanine-DNA methyltransferase (MGMT), a contributing factor for very poor survival in GBM patients [28], we investigated a possible role of miR-340 in TMZ sensitivity. The gene discussed is MGMT; the disease is glioblastoma.